Survival effect of probiotics in a rat model of colorectal cancer treated with capecitabine

Table 1 Clinicopathological characteristics of animals per group, n (%)

	Control (n = 5)	Control-P (n = 5)	DMH (n = 10)	DMH-C (n = 9)	DMH-P (n = 10)	DMH-C-P (n = 9)
Clinical manifestations
Diarrhea	-	-	3 (30)	2 (22)	1 (10)	-
Constipation	-	-	3 (30)	-	3 (30)	-
Blood stool	-	-	2 (20)	-	4 (40)	-
No manifestations	-	-	2 (20)	7 (78)	2 (20)	9 (100)
Tumor location
Left colon	-	-	7 (70)	3 (33)	5 (63)	2 (22)
Right colon	-	-	1 (10)	1 (11)	2 (25)	2 (22)
Rectum	-	-	2 (20)	-	1 (12)	-
Histological type
Adenocarcinoma	-	-	5 (50)	-	6 (75)	-
Mucinous	-	-	2 (20)	4 (44)	2 (25)	4 (44)
Mixed	-	-	2 (20)	-	-	-
SRCC	-	-	1 (10)	-	-	-
Average tumor size/animal	-	-	2.5	1.0	2.1	1.0
Tumoral burden (cm2)	-	-	4.8	1.81	3.9	1.25
Number of nodes involved in the total number of animals	-	-	4	2	4	-

SRCC: Signet ring cell carcinoma; DMH: 1,2-Dimethylhidrazine dihydrochloride; P: Probiotics; C: Capecitabine.